CIBC Asset Management’s Ginkgo Bioworks DNA Stock Holding History

CIBC Asset Management’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,139	Closed	-$15.2K	–	1216
2024 Q2	$15.2K	Buy	1,139 +511	+81%	+$15.2K	﹤0.01%	1143
2024 Q1	$29.1K	Hold	628	–	–	﹤0.01%	1119
2023 Q4	$42.5K	Hold	628	–	–	﹤0.01%	1079
2023 Q3	$45.5K	Hold	628	–	–	﹤0.01%	1026
2023 Q2	$46.7K	Hold	628	–	–	﹤0.01%	1069
2023 Q1	$33.4K	Sell	628 -155	-20%	-$9.82K	﹤0.01%	1048
2022 Q4	$52.9K	Sell	783 -1,109	-59%	-$102K	﹤0.01%	1033
2022 Q3	$236K	Hold	1,892	–	–	﹤0.01%	990
2022 Q2	$180K	Sell	1,892 -138	-7%	-$16.8K	﹤0.01%	1144
2022 Q1	$327K	Hold	2,030	–	–	﹤0.01%	1010
2021 Q4	$675K	Buy	+2,030	New	+$964K	﹤0.01%	775

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CIBC Asset Management's DNA Position: Q3 2024 in Review

CIBC Asset Management sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 1,139 shares — an estimated $15.2K sold.

CIBC Asset Management first reported a position in DNA in Q4 2021 and held it in 11 quarters. The position peaked at $675K in Q4 2021. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

CIBC Asset Management reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
CIBC Asset Management sold 1,139 Ginkgo Bioworks shares in Q3 2024, an estimated $15.2K.
CIBC Asset Management first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 11 quarters.
CIBC Asset Management's Ginkgo Bioworks position peaked at $675K in Q4 2021.
159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on CIBC Asset Management's 13F filing for Q3 2024, filed 6 Nov 2024.